A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute …

K Tsuboi, T Yokozawa, T Sakura, T Watanabe… - Leukemia research, 2011 - Elsevier
Barasertib (AZD1152) is a highly potent and selective Aurora B kinase inhibitor. The safety,
efficacy and pharmacokinetic (PK) profile of barasertib were investigated in Japanese
patients with advanced acute myeloid leukemia. Barasertib (50–1200mg) was administered
as a continuous 7-day intravenous infusion every 21 days. No dose-limiting toxicities were
reported and barasertib 1200mg was chosen for further evaluation in Japanese patients.
Neutropenia and febrile neutropenia were the most commonly reported adverse events. The …